Brief: Acura Pharmaceuticals enters license, development agreement with Bayer Healthcare
16/06/2015 11:15
June 16 (Reuters) - Acura Pharmaceuticals Inc ACUR.O : * Partners its methamphetamine resistant Impede(R) technology * Entered license and development agreement with Bayer healthcare to provide worldwide license to acura's impede technology * Says Bayer has the right to negotiate for a worldwide license to the impede technology for additional products * Agreement with Bayer healthcare to jointly develop product utilizing the impede technology for U.S. market * Source text for Eikon ID:nCCNbMGXBK * Further company coverage ACUR.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Acura Pharmaceuticals
See all newsBrief: Acura Pharmaceuticals Received A $250,000 Loan From Abuse Deterrent Pharma, LLC on October 11
Brief: Acura Pharmaceuticals Inc Receives $200,000 Loan From Abuse Deterrent Pharma
Brief: Acura Pharmaceuticals Received $250,000 Loan From AD Pharma For Operations Through End Of April 2023
Brief: Acura Pharmaceuticals, AD Pharma Amend License to LIMITx LTX-03
Insight: Novavax bosses cash out for $46 mln with COVID-19 vaccine trials still under way